Trial Profile
An obsevational study of EGFR mutation status by circulating tumor DNA and tissue during the osimertinib treatment in poor PS patients with T790M positive advanced NSCLC
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 30 Sep 2021 Status changed from recruiting to completed.
- 19 Jan 2017 New trial record